Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Flawless balance sheet with solid track record.
Share Price & News
How has Cochlear's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: COH's share price has been volatile over the past 3 months.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: COH underperformed the Australian Medical Equipment industry which returned 10.2% over the past year.
Return vs Market: COH exceeded the Australian Market which returned -11.2% over the past year.
Price Volatility Vs. Market
How volatile is Cochlear's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St4 Days To Buy Cochlear Limited (ASX:COH) Before The Ex-Dividend Date
2 months ago | Simply Wall StHere's What Cochlear Limited's (ASX:COH) P/E Is Telling Us
2 months ago | Simply Wall StShould You Like Cochlear Limited’s (ASX:COH) High Return On Capital Employed?
Is Cochlear undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: COH (A$187.93) is trading above our estimate of fair value (A$186)
Significantly Below Fair Value: COH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: COH is poor value based on its PE Ratio (35.5x) compared to the Medical Equipment industry average (26x).
PE vs Market: COH is poor value based on its PE Ratio (35.5x) compared to the Australian market (15x).
Price to Earnings Growth Ratio
PEG Ratio: COH is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: COH is overvalued based on its PB Ratio (13.5x) compared to the AU Medical Equipment industry average (4.2x).
How is Cochlear forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COH's forecast earnings growth (47% per year) is above the savings rate (2.3%).
Earnings vs Market: COH's earnings (47% per year) are forecast to grow faster than the Australian market (14.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: COH's revenue (14.9% per year) is forecast to grow faster than the Australian market (4.3% per year).
High Growth Revenue: COH's revenue (14.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: COH's Return on Equity is forecast to be high in 3 years time (27.3%)
How has Cochlear performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: COH has a high level of non-cash earnings.
Growing Profit Margin: COH's current net profit margins (20.7%) are higher than last year (18.6%).
Past Earnings Growth Analysis
Earnings Trend: COH's earnings have grown by 14.6% per year over the past 5 years.
Accelerating Growth: COH's earnings growth over the past year (16.1%) exceeds its 5-year average (14.6% per year).
Earnings vs Industry: COH earnings growth over the past year (16.1%) exceeded the Medical Equipment industry 14.7%.
Return on Equity
High ROE: COH's Return on Equity (37.9%) is considered high.
How is Cochlear's financial position?
Financial Position Analysis
Short Term Liabilities: COH's short term assets (A$653.9M) exceed its short term liabilities (A$349.7M).
Long Term Liabilities: COH's short term assets (A$653.9M) exceed its long term liabilities (A$487.2M).
Debt to Equity History and Analysis
Debt Level: COH's debt to equity ratio (29%) is considered satisfactory.
Reducing Debt: COH's debt to equity ratio has reduced from 71.7% to 29% over the past 5 years.
Debt Coverage: COH's debt is well covered by operating cash flow (110.7%).
Interest Coverage: COH's interest payments on its debt are well covered by EBIT (54.2x coverage).
What is Cochlear's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: COH's dividend (1.76%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.64%).
High Dividend: COH's dividend (1.76%) is low compared to the top 25% of dividend payers in the Australian market (6.77%).
Stability and Growth of Payments
Stable Dividend: COH's dividend payments have been volatile in the past 10 years.
Growing Dividend: COH's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (63.3%), COH's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of COH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dig Howitt (52yo)
Mr. Diggory William Howitt, also known as Dig, BE (Hons), MBA has been President of Cochlear Limited since July 31, 2017 and its Chief Executive Officer and Managing Director since January 3, 2018. Mr. How ...
CEO Compensation Analysis
Compensation vs Market: Dig's total compensation ($USD2.46M) is about average for companies of similar size in the Australian market ($USD2.84M).
Compensation vs Earnings: Dig's compensation has been consistent with company performance over the past year.
|CEO, MD||2.33yrs||AU$3.69m||0.065% A$8.0m|
|Chief Financial Officer||3.17yrs||AU$1.09m||no data|
|Chief Technology Officer||2.5yrs||AU$1.55m||0.010% A$1.3m|
|President of EMEA & Latin American Region||no data||AU$1.86m||0.010% A$1.3m|
|President of Americas Region||4.08yrs||AU$1.49m||0.0033% A$409.8k|
|President of Asia Pacific Region||3.83yrs||AU$940.84k||0.0011% A$140.7k|
|Chief Information Officer||4.83yrs||no data||no data|
|Head of Investor Relations||no data||no data||no data|
|Head of Corporate Communications||no data||no data||no data|
|Senior Vice President of Global Marketing||3.92yrs||no data||no data|
Experienced Management: COH's management team is considered experienced (3.8 years average tenure).
|CEO, MD||2.33yrs||AU$3.69m||0.065% A$8.0m|
|Independent Non-Executive Director||13.25yrs||AU$266.22k||0.0064% A$792.5k|
|Independent Non-Executive Director||0.33yr||no data||0.0019% A$228.4k|
|Independent Non-Executive Director||14.75yrs||AU$245.85k||0.0095% A$1.2m|
|Independent Chairman||9.83yrs||AU$526.15k||0.016% A$1.9m|
|Independent Non-Executive Director||5.33yrs||AU$251.07k||0.0049% A$603.7k|
|Independent Non-Executive Director||9.75yrs||AU$276.22k||0.0056% A$697.5k|
|Independent Non-Executive Director||3.42yrs||AU$256.22k||0.0028% A$350.6k|
|Independent Non-Executive Director||5.33yrs||AU$271.22k||0.0046% A$566.6k|
|Non-Executive Independent Director||1.42yrs||AU$122.61k||0.00034% A$42.0k|
Experienced Board: COH's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.8%.
Cochlear Limited's company bio, employee growth, exchange listings and data sources
- Name: Cochlear Limited
- Ticker: COH
- Exchange: ASX
- Founded: 1981
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$12.345b
- Shares outstanding: 65.69m
- Website: https://www.cochlear.com
Number of Employees
- Cochlear Limited
- 1 University Avenue
- Macquarie University
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CHEO.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Dec 1995|
|COH||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 1995|
|OC5||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 1995|
|COH||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 1995|
|CHEO.Y||OTCPK (Pink Sheets LLC)||UNSPONSORD ADR||US||USD||Jan 2009|
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, Baha 5 power, Baha 5 superpower, other sound processors, and wireless accessories. It also provides Cochlear true wireless devices comprising mini microphones, phone clips, and TV streamers; and Cochlear Vistafix bone-anchored facial prosthetic solutions to enhance the attachment and cosmetic outcome of facial prostheses. The company has strategic collaboration with GN Hearing to develop integrated hearing solutions. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/28 10:34|
|End of Day Share Price||2020/05/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.